GENMAB A/S -SP ADR (GMAB:NASDAQ)
$28.84 0.04 (0.1389%)
Analysed GENMAB A/S -SP ADR (GMAB:NASDAQ) News Sources
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
13-06-2026
yahoo.com
Genmab’s EPCORE Data Deepens Lymphoma Profile As Investors Weigh Upside
15-06-2026
yahoo.com
Major Shareholder Announcement
15-06-2026
yahoo.com
Capital Increase in Genmab as a Result of Employee Warrant Exercise
16-06-2026
yahoo.com
VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026
18-06-2026
yahoo.com
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
29-06-2026
yahoo.com
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
06-07-2026
yahoo.com
Exchange-Traded Funds Lower, Equity Futures Mixed Amid Caution Over Chip Sector Outlook
07-07-2026
yahoo.com
Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?
08-07-2026
yahoo.com
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
13-07-2026
yahoo.com
What is the current price of GENMAB A/S -SP ADR (GMAB:NASDAQ)?
The current price of GENMAB A/S -SP ADR (GMAB:NASDAQ) is $28.84.
GENMAB A/S -SP ADR (GMAB:NASDAQ) absolute price change since previous trading day?
The absolute price change of GENMAB A/S -SP ADR (GMAB:NASDAQ) since the previous trading day is $0.04.
GENMAB A/S -SP ADR (GMAB:NASDAQ) percentage price change since previous trading day?
The percentage price change of GENMAB A/S -SP ADR (GMAB:NASDAQ) since the previous trading day is 0.1389%.
What is the most recent average sentiment score for GENMAB A/S -SP ADR (GMAB:NASDAQ)?
The most recent average sentiment score for GENMAB A/S -SP ADR (GMAB:NASDAQ) is 66 out of 100.
What is the most recent average sentiment for GENMAB A/S -SP ADR (GMAB:NASDAQ)?
The most recent sentiment for GENMAB A/S -SP ADR (GMAB:NASDAQ) is .
SEC-8K** Filing Available For GENMAB A/S -SP ADR (GMAB:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.